These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 3475378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The mechanism of the increase in the serum CA125 concentration in patients with endometriosis].
    Kobayashi H, Miyake W, Yamashita M, Kanayama N, Hayata T, Kawashima Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):467-72. PubMed ID: 3163715
    [Abstract] [Full Text] [Related]

  • 4. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
    Iwasaka T, Ohkuma Y, Yoshimura T, Sugimori H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
    Kuzuya K, Nozaki M, Chihara T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
    [Abstract] [Full Text] [Related]

  • 6. Serum CA 125 as a marker for patients with external endometriosis.
    Takahashi K, Kijima S, Yoshino K, Shibukawa T, Kitao M.
    Int J Fertil; 1989 Jun; 34(2):143-8. PubMed ID: 2565317
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y, Akagaki E, Hirota K, Kono M, Miura S, Okudaira Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
    [Abstract] [Full Text] [Related]

  • 9. [Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma].
    Takahashi K, Kijima S, Yoshino K, Shibukawa T, Moriyama M, Iwanari O, Sawada K, Matsunaga I, Murao F, Kitao M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Apr; 37(4):591-5. PubMed ID: 3857281
    [Abstract] [Full Text] [Related]

  • 10. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H, Masuda T, Hattori A, Noguchi M, Ito Y, Nakanishi M, Ishihara M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [Abstract] [Full Text] [Related]

  • 11. [Fundamental and clinical study on source of CA 125 antigen in cul-de-sac fluid and translation into systemic circulation].
    Kobayashi H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):390-6. PubMed ID: 2746065
    [Abstract] [Full Text] [Related]

  • 12. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K, Yasui Y, Asai H, Hisaoka T, Mizuno K, Yagami Y.
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [Abstract] [Full Text] [Related]

  • 13. [Value of CA125 (carbon hydrate tumor-associated antigen) and endometrial antibodies for the detections of endometriosis].
    Yang F, Fang AH, Gu RF.
    Zhonghua Fu Chan Ke Za Zhi; 1994 Mar; 29(3):147-9, 189. PubMed ID: 8082430
    [Abstract] [Full Text] [Related]

  • 14. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
    Chen DX, Li FQ.
    Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
    [Abstract] [Full Text] [Related]

  • 15. [The clinical usefulness of the measurement of serum sialyl SSEA-1 antigen levels in patients with gynecologic diseases: as respects the comparative effectiveness of sialyl SSEA-1 and CA125].
    Kobayashi H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):828-34. PubMed ID: 3166483
    [Abstract] [Full Text] [Related]

  • 16. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
    Kawai M, Yamashita H, Hayashi T, Kamiya N, Kakihara M, Arii Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
    [Abstract] [Full Text] [Related]

  • 17. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
    Stratton JA, Rettenmaier MA, Phillips HB, Herabutya S, DiSaia PJ.
    Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
    [Abstract] [Full Text] [Related]

  • 18. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
    Inaba N, Okajima Y, Ota Y, Fukazawa I, Yamaguchi T, Sato N, Sudo H, Milanga M, Takamizawa H, Fujii S.
    Nihon Gan Chiryo Gakkai Shi; 1989 Oct 20; 24(10):2426-35. PubMed ID: 2614181
    [Abstract] [Full Text] [Related]

  • 19. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report.
    Kafali H, Artuc H, Demir N.
    Eur J Obstet Gynecol Reprod Biol; 2004 Sep 10; 116(1):85-8. PubMed ID: 15294374
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.